Efforts to reshore U.S. pharmaceutical manufacturing are hitting a wall, but the problem is not a lack of factories. According to MedCity News, the real bottleneck is talent. The industry faces a shortage of skilled workers capable of operating and scaling domestic production, and that shortage is now the critical limiting factor.
The article argues that pharma leaders need to adopt a "construction crew" mindset, treating workforce development with the same urgency and strategic importance as physical infrastructure. Just as building a plant requires planning, investment, and a timeline, so does building the pipeline of trained workers to staff it.
Without this shift, reshoring initiatives risk stalling even as new facilities come online. The message is clear: factories are only as valuable as the people who can run them, and the industry must start investing in human capital as deliberately as it invests in concrete and steel.